Literature DB >> 3548246

Intravenous therapy with gamma globulin.

J M Dwyer.   

Abstract

The availability of intravenous gamma globulin preparations that are safe and effective has revolutionized replacement therapy in those patients suffering primary or secondary hypogammaglobulinemia. The potential for controlling numerous autoimmune reactions with high-dose gamma globulin infusion is exciting and challenging. Unraveling the immunoregulatory mechanisms that interact with large doses of human IgG may teach us much about immunoregulation in general and the immunopathogenic mechanisms that lead to chronic disease for so many.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3548246

Source DB:  PubMed          Journal:  Adv Intern Med        ISSN: 0065-2822


  5 in total

1.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

2.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

3.  Intravenous immune globulin use in children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1992-01-15       Impact factor: 8.262

4.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

5.  High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.

Authors:  S Jann; S Beretta; M Moggio; L Adobbati; G Pellegrini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-01       Impact factor: 10.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.